Akos Czibere

Chief Tech/Sci/R&D Officer at AKTIS ONCOLOGY, INC.

Net worth: - $ as of 2026-08-30

48 year

Health Technology

Consumer Services

Profile

Akos Czibere currently works at Aktis Oncology, Inc., as Chief Medical Officer from 2024.
Dr. Czibere also formerly worked at Merrimack Pharmaceuticals, Inc., as Vice President-Clinical Development and Pfizer Inc., as Vice President-Therapeutic Area.
Dr. Czibere received his doctorate degree from Heinrich-Heine-Universität Düsseldorf.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
AKTIS ONCOLOGY, INC. -.--%	2026-09-22	0 ( -.--% )	- $	2026-08-30

Akos Czibere active positions

Companies	Position	Start
AKTIS ONCOLOGY, INC.	Chief Tech/Sci/R&D Officer	2024-06-30

All active positions of Akos Czibere

Former positions of Akos Czibere

Companies	Position	End
PFIZER INC.	Corporate Officer/Principal	-
MERRIMACK PHARMACEUTICALS	Corporate Officer/Principal	-

See the detail of Akos Czibere's experience

Training of Akos Czibere

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Akos Czibere's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Pfizer Inc. Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients	Health Technology
Merrimack Pharmaceuticals, Inc. Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer	Health Technology
Heinrich-Heine-Universität Düsseldorf Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Aktis Oncology, Inc. Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers	Health Technology